Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Deffered Revenue (2021 - 2023)

Spyre Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $2.3 million for Q2 2023.

  • For Q2 2023, Non-Current Deffered Revenue fell 1.31% year-over-year to $2.3 million; the TTM value through Jun 2023 reached $2.3 million, down 1.31%, while the annual FY2022 figure was $2.2 million, 79.05% up from the prior year.
  • Non-Current Deffered Revenue reached $2.3 million in Q2 2023 per SYRE's latest filing, roughly flat from $2.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $2.4 million in Q2 2022 to a low of $740000.0 in Q1 2022.
  • Average Non-Current Deffered Revenue over 3 years is $2.0 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 67.46% in 2022, then surged 216.35% in 2023.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $1.2 million in 2021, then skyrocketed by 79.05% to $2.2 million in 2022, then rose by 7.43% to $2.3 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Non-Current Deffered Revenue are $2.3 million (Q2 2023), $2.3 million (Q1 2023), and $2.2 million (Q4 2022).